Mustang Bio’s optimized CAR-T therapy shows encouraging action in preclinical testing; shares ahead 3% – Seeking Alpha
registrarjournal.com |
Mustang Bio's optimized CAR–T therapy shows encouraging action in preclinical testing; shares ahead 3%
Seeking Alpha The study, conducted at the City of Hope National Medical Center, showed a greater antitumor effect for Mustang's CD4+ CAR T cells compared to CD8+ CAR T cells. A Phase 1 trial in glioblastoma, the most aggressive type of brain tumor, is ongoing. Mustang Bio (NASDAQ:MBIO) Lifted to “Buy” at Zacks Investment Research |
